糖皮质激素治疗下可行走杜氏肌营养不良男孩的不同骨健康进展模式及早期风险标志物
该回顾性纵向队列研究纳入153名在华西第二医院就诊的杜氏肌营养不良(DMD)男孩(2016—2023年),采用基于组的轨迹模型分析骨密度(BMD)进展模式,发现3种BMD轨迹,基线BMD和糖皮质激素起始年龄是轨迹归因的独立预测因素,BMD可作为监测骨脆性的早期指标。
要点
- 在153名DMD男孩中识别出3种BMD进展轨迹。
- 基线BMD和糖皮质激素起始年龄是轨迹归因的独立预测因素。
- 糖皮质激素治疗DMD男孩首次观察到低BMD的中位生存时间为5.32年(95%CI 4.05-6.59)。
核心结论
- BMD可能作为监测DMD骨脆性的新型早期指示标志物。
- 作者提出通过BMD进展轨迹进行骨健康风险分层,使DMD的骨质疏松警示从固定阈值方法转向更个体化的策略,其中基线BMD和糖皮质激素起始年龄可提供骨丢失的早期预测。
- 更好地管理基线BMD可能延迟或避免DMD儿童第五年时不良骨健康结局的发生。
研究设计与样本
- 回顾性纵向队列研究,纳入2016—2023年华西第二大学医院153名DMD男孩。
- 采用基于组的轨迹模型研究BMD进展模式,并通过逻辑回归和生存分析进一步分析潜在预测因素。
主要发现
- 共纳入153名参与者,其中71名有超过3次BMD记录。
- 识别出3种BMD轨迹。
- 基线BMD和糖皮质激素起始年龄是轨迹归因的独立预测因素。
- 糖皮质激素治疗DMD男孩首次观察到低BMD的中位生存时间为5.32年(95%CI 4.05-6.59),3个轨迹组间差异有统计学意义(P < 0.001)。
临床怎么用
- 作者提出通过BMD进展轨迹进行骨健康风险分层,使DMD的骨质疏松警示从固定阈值方法转向更个体化的策略。
- 作者认为基线BMD和糖皮质激素起始年龄可提供骨丢失的早期预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Fractures often cause irreversible harm in Duchenne muscular dystrophy (DMD). This study investigated the trajectory of bone mineral density (BMD) using group-based trajectory modeling and identified that BMD acts as an early-stage indicator of clinically significant bone fragility. The greater the early-stage BMD, the better the 4-year bone health outcome. PURPOSE: Most Duchenne muscular dystrophy (DMD) children suffer bone loss after long-term glucocorticoid (GC) exposure, which induces scoliosis and fragility fractures. To assess the BMD progression pattern and individual medical risk markers for these phenotypes in young ambulatory boys with DMD, and provide evidence-based suggestions for clinical management of bone health. METHODS: A retrospective longitudinal cohort study of 153 boys with DMD in West China Second University Hospital (2016-2023) was performed. Group-based trajectory modeling was used to study the BMD progression pattern, and potential predictors were further analyzed by logistic regression and survival analysis. RESULTS: One hundred and fifty-three participants were included, 71 of which had more than 3 BMD records. Three BMD trajectories were identified. Baseline BMD and age-started GC and were independent predictors of trajectory attribution. The median survival time of the first observation of low BMD in GC-treated DMD boys was 5.32 (95% CI 4.05-6.59) years, and a significant difference was tested (P < 0.001) among the three trajectory groups. CONCLUSION: BMD may serve as a novel early indicating marker for monitoring bone fragility for DMD. We proposed a bone health risk stratification through BMD progression trajectory that allows us to adapt the osteoporosis warning sign in DMD from a fixed threshold approach to a more individualized strategy, where baseline BMD and age of glucocorticoid initiation can provide an earlier prediction of bone loss. Better management of primary BMD may be able to delay or avoid the onset of adverse bone health outcomes in the fifth year in children with DMD.
引用
- Zhou L, Zhou H, Xu H, et al. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy. Osteoporos Int. 2024. PMID: 38277031. doi:10.1007/s00198-024-07018-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。